Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home (PROBELDERLY)

Universidad Complutense de Madrid

Status: Unknown

Conditions: Covid19

Treatments: Biological: Ligilactobacillus salivarius MP101

Study type: Interventional

Funder types: Other

Identifiers

NCT04922918

CEIC 20/263-E_COVID

Details and patient eligibility

About

The objective of this work was to investigate the effect of Ligilactobacillus salivarius MP101 on the functional (Barthel index), cognitive (GDS/FAST) and nutritional (MNA) status, and on the nasal and fecal inflammatory profiles of elderly living in a nursing home highly affected by COVID-19.

Enrollment: 25 estimated patients

Sex: All

Ages: 74 to 98 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Living in the nursing home
• Informed consent obtained

Exclusion criteria

• Absence of informed consent
• Parenteral nutrition (exclusively)
• Allergy to cow's milk protein

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Probiotic arm

Experimental group

Description:

Administration of Ligilactobacillus salivarius MP101 (\>9 log10cfu, daily) for 4 months

Treatment:

Biological: Ligilactobacillus salivarius MP101